PortalPublikationenAntilymphocyte Globulin for matched sibling donor transplant...

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis

Standard

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis. / Robin, Marie; Chevret, Sylvie; Koster, Linda; Wolschke, Christine; Yakoub-Agha, Ibrahim; Bourhis, Jean-Henri; Chevallier, Patrice; Cornelissen, Jan J; Reményi, Péter; Maertens, Johan; Poiré, Xavier; Craddock, Charles; Socié, Gérard; Itälä-Remes, Maija; Schouten, Harry C; Marchand, Tony; Passweg, Jakob; Blaise, Didier; Damaj, Gandhi; Ozkurt, Zubeyde Nur; Zuckerman, Tsila; Cluzeau, Thomas; Labussière-Wallet, Hélène; Cammenga, Jörg; McLornan, Donal; Chalandon, Yves; Kröger, Nicolaus.

in: HAEMATOLOGICA, Jahrgang 104, Nr. 6, 06.2019, S. 1230-1236.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Robin, M, Chevret, S, Koster, L, Wolschke, C, Yakoub-Agha, I, Bourhis, J-H, Chevallier, P, Cornelissen, JJ, Reményi, P, Maertens, J, Poiré, X, Craddock, C, Socié, G, Itälä-Remes, M, Schouten, HC, Marchand, T, Passweg, J, Blaise, D, Damaj, G, Ozkurt, ZN, Zuckerman, T, Cluzeau, T, Labussière-Wallet, H, Cammenga, J, McLornan, D, Chalandon, Y & Kröger, N 2019, 'Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis', HAEMATOLOGICA, Jg. 104, Nr. 6, S. 1230-1236. https://doi.org/10.3324/haematol.2018.201400

APA

Robin, M., Chevret, S., Koster, L., Wolschke, C., Yakoub-Agha, I., Bourhis, J-H., Chevallier, P., Cornelissen, J. J., Reményi, P., Maertens, J., Poiré, X., Craddock, C., Socié, G., Itälä-Remes, M., Schouten, H. C., Marchand, T., Passweg, J., Blaise, D., Damaj, G., ... Kröger, N. (2019). Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis. HAEMATOLOGICA, 104(6), 1230-1236. https://doi.org/10.3324/haematol.2018.201400

Vancouver

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis J-H et al. Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis. HAEMATOLOGICA. 2019 Jun;104(6):1230-1236. https://doi.org/10.3324/haematol.2018.201400

Bibtex

@article{9a3ad169b09b4809a5d29b42cc5fa880,
title = "Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis",
abstract = "The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft- versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n=287). The cumulative incidences of grade II-IV acute graft- versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft- versus-host disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graft- versus-host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P=0.010) while it did not decrease the risk of chronic graft- versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft- versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft- versus-host disease without increasing the risk of relapse. ",
keywords = "Journal Article",
author = "Marie Robin and Sylvie Chevret and Linda Koster and Christine Wolschke and Ibrahim Yakoub-Agha and Jean-Henri Bourhis and Patrice Chevallier and Cornelissen, {Jan J} and P{\'e}ter Rem{\'e}nyi and Johan Maertens and Xavier Poir{\'e} and Charles Craddock and G{\'e}rard Soci{\'e} and Maija It{\"a}l{\"a}-Remes and Schouten, {Harry C} and Tony Marchand and Jakob Passweg and Didier Blaise and Gandhi Damaj and Ozkurt, {Zubeyde Nur} and Tsila Zuckerman and Thomas Cluzeau and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and J{\"o}rg Cammenga and Donal McLornan and Yves Chalandon and Nicolaus Kr{\"o}ger",
note = "Copyright {\textcopyright} 2019, Ferrata Storti Foundation.",
year = "2019",
month = jun,
doi = "10.3324/haematol.2018.201400",
language = "English",
volume = "104",
pages = "1230--1236",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

RIS

TY - JOUR

T1 - Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis

AU - Robin, Marie

AU - Chevret, Sylvie

AU - Koster, Linda

AU - Wolschke, Christine

AU - Yakoub-Agha, Ibrahim

AU - Bourhis, Jean-Henri

AU - Chevallier, Patrice

AU - Cornelissen, Jan J

AU - Reményi, Péter

AU - Maertens, Johan

AU - Poiré, Xavier

AU - Craddock, Charles

AU - Socié, Gérard

AU - Itälä-Remes, Maija

AU - Schouten, Harry C

AU - Marchand, Tony

AU - Passweg, Jakob

AU - Blaise, Didier

AU - Damaj, Gandhi

AU - Ozkurt, Zubeyde Nur

AU - Zuckerman, Tsila

AU - Cluzeau, Thomas

AU - Labussière-Wallet, Hélène

AU - Cammenga, Jörg

AU - McLornan, Donal

AU - Chalandon, Yves

AU - Kröger, Nicolaus

N1 - Copyright © 2019, Ferrata Storti Foundation.

PY - 2019/6

Y1 - 2019/6

N2 - The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft- versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n=287). The cumulative incidences of grade II-IV acute graft- versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft- versus-host disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graft- versus-host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P=0.010) while it did not decrease the risk of chronic graft- versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft- versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft- versus-host disease without increasing the risk of relapse.

AB - The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft- versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis (n=287). The cumulative incidences of grade II-IV acute graft- versus-host disease among patients who were or were not given antihuman T-lymphocyte immunoglobulin were 26% and 41%, respectively. The corresponding incidences of chronic graft- versus-host disease were 52% and 55%, respectively. Non-adjusted overall survival, disease-free survival and non-relapse mortality rates were 55% versus 53%, 49% versus 45%, and 32% versus 31%, respectively, among the patients who were or were not given antihuman T-lymphocyte immunoglobulin. An adjusted model confirmed that the risk of acute graft- versus-host disease was lower following antihuman T-lymphocyte immunoglobulin (hazard ratio, 0.54; P=0.010) while it did not decrease the risk of chronic graft- versus-host disease. The hazard ratios for overall survival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not influence disease-free survival, graft- versus-host disease, relapse-free survival or relapse risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this study demonstrates that antihuman T-lymphocyte immunoglobulin decreases the risk of acute graft- versus-host disease without increasing the risk of relapse.

KW - Journal Article

U2 - 10.3324/haematol.2018.201400

DO - 10.3324/haematol.2018.201400

M3 - SCORING: Journal article

C2 - 30655365

VL - 104

SP - 1230

EP - 1236

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 6

ER -